CompletedPhase 2

Study of ATH434 in Participants with Multiple System Atrophy

United States77 participantsStarted 2022-07-01

Plain-language summary

This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Participant has clinical features of parkinsonism.
✓. Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
✓. Participant has ataxia and/or pyramidal signs on neurological examination.
✓. Participant is ambulatory.
✓. Participant has biomarker evidence of MSA in biologic fluid and on MRI.

✕. Participant has motor symptoms for \> 4 years.
✕. Participant has advanced disease, as indicated by frequent falls or choking.
✕. Participant has structural brain abnormality on MRI.
✕. Participant has any significant neurological disorder other than MSA.
✕. Participant has an unstable medical or psychiatric illness.
✕. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture.

Change in iron content as measured by brain MRI

Timeframe: Change from Baseline to Week 52

NCT IDNCT05109091

SponsorAlterity Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-11-28